ONCO
Onconetix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
High Gross Profit Margin
Significant Net Income Decline
Low Cash Short-term Debt Ratio
Shooting Star
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ONCO
Onconetix, Inc.
A biotech company that develops vaccines to treat influenza and mosquito-borne diseases
201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202
--
Onconetix, Inc., was incorporated in Delaware on October 26, 2018. The Company is a commercial-stage biotechnology company focused on the research, development and commercialization of oncology proprietary therapies, diagnostics and services for clinicians and patients. The company currently owns EntadFi, an FDA-approved oral treatment for benign prostatic hyperplasia (BPH), a prostate disease, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosing men with indeterminate prostate-specific antigen (PSA) assessment in prostate cancer oncology.
Company Financials
EPS
ONCO has released its 2025 Q3 earnings. EPS was reported at -6.25, versus the expected 0, missing expectations. The chart below visualizes how ONCO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ONCO has released its 2025 Q3 earnings report, with revenue of 303.65K, reflecting a YoY change of -25.37%, and net profit of -8.78M, showing a YoY change of -129.49%. The Sankey diagram below clearly presents ONCO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
